← 返回

多模态分析揭示与 RBM27 相关的肝细胞癌免疫抑制并构建预后模型

英文原题:Multimodal Analysis Reveals Immune Suppression Associated With Hepatocellular Carcinoma Related to RBM27 and Constructs a Prognostic Model.

查看英文原题

Multimodal Analysis Reveals Immune Suppression Associated With Hepatocellular Carcinoma Related to RBM27 and Constructs a Prognostic Model.

PubMed 2026/03/23(内容时间) Hum Mutat Q4 · IF 1.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究思路按摘要原文分段

肝细胞癌(HCC)由于免疫抑制微环境而表现出侵袭性进展和治疗耐药。RNA结合基序蛋白27(RBM27)被认为参与RNA加工,但其在HCC免疫逃逸中的作用尚未被阐明。

多组学分析(TCGA/GEO、单细胞/空间转录组学)与功能验证(体外/体内)相结合。评估了RBM27在HCC组织/细胞系中的表达。敲低模型(慢病毒shRNA)评估了对增殖、迁移、侵袭(Transwell/伤口愈合)和肿瘤生长(异种移植)的影响。进行了免疫谱分析(ssGSEA/TIP)、代谢通路(GSEA/KEGG)和预后建模(Cox/列线图)。空间转录组学映射了免疫微环境改变。

与邻近非肿瘤组织相比,RBM27在HCC组织中的表达水平显著上调。基因组分析显示,这种上调由拷贝数变异(CNVs)驱动,尤其是基因扩增,并伴有特定的突变模式。这种异常上调与疾病晚期临床分期、AFP升高和生存期差(OS/DSS/PFI;p < 0.05)密切相关。敲低RBM27可抑制HCC增殖、迁移、侵袭和异种移植瘤生长。机制上,RBM27激活氧化磷酸化,通过CD8+ T细胞和NK细胞耗竭、Treg/Th2富集以及癌症-免疫循环步骤受损来驱动免疫抑制。空间分析证实了RBM27 + 恶性生态位伴有淋巴细胞排斥。纳入RBM27的预后列线图(C - index = 0.688)可预测1年/3年/5年生存率。

由包括基因扩增在内的遗传改变驱动,RBM27通过OXPHOS激活重塑免疫抑制微环境,促进HCC进展,可作为诊断和预后的生物标志物以及潜在的治疗靶点,有助于对抗免疫逃逸。

展开英文摘要原文

Hepatocellular carcinoma (HCC) exhibits aggressive progression and therapy resistance due to immunosuppressive microenvironments. RNA-binding motif protein 27 (RBM27) is implicated in RNA processing, yet its role in HCC immune evasion remains uncharacterized.

Multiomics analyses (TCGA/GEO, single-cell/spatial transcriptomics) were integrated with functional validation (in vitro/vivo). RBM27 expression was assessed in HCC tissues/cell lines. Knockdown models (lentiviral shRNA) evaluated impacts on proliferation, migration, invasion (Transwell/wound healing), and tumor growth (xenografts). Immune profiling (ssGSEA/TIP), metabolic pathways (GSEA/KEGG), and prognostic modeling (Cox/nomogram) were performed. Spatial transcriptomics mapped immune niche alterations.

Compared with adjacent nontumor tissues, the expression level of RBM27 was markedly overexpressed in HCC tissues. Genomic analysis revealed that this upregulation is driven by copy number variations (CNVs), particularly gene amplification, alongside specific mutational patterns. This abnormal upregulation was closely correlated with advanced clinical stages of the disease, elevated AFP, and poor survival (OS/DSS/PFI; p < 0.05). RBM27 knockdown suppressed HCC proliferation, migration, invasion, and xenograft growth. Mechanistically, RBM27 activated oxidative phosphorylation, driving immunosuppression via CD8+ T cell and NK cell depletion, Treg/Th2 enrichment, and impaired cancer-immunity cycle steps. Spatial analysis confirmed RBM27 + malignant niches with lymphoid exclusion. A prognostic nomogram (C - index = 0.688) incorporating RBM27 predicted 1-/3-/5-year survival.

Driven by genetic alterations including gene amplification, RBM27 promotes HCC progression by remodeling an immunosuppressive microenvironment via OXPHOS activation, acting as a biomarker for diagnosis and prognosis along with a potential therapeutic target, it could assist in combating immune escape.

论文信息

作者
Gao W、Cong D、Chen X、Wang X、Duan T、Zhao X、Wang D、Liu W
第一作者单位
Department of Gastroenterology, The 962th Hospital of the PLA Joint Logistic Support Force, Harbin, China.China
通讯作者单位
Department of Infectious Diseases, The 962th Hospital of the PLA Joint Logistic Support Force, Harbin, China.China
期刊
Human mutation2026
原文标识
PubMed 42459515 · DOI 10.1155/humu/4343678